drugset / Trial / NCT06257966
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study is to compare the efficacy and safety of two JY09 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)
Timeline
- Start
- 2024-07-17
- Primary completion
- 2026-10-01
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |
| Subject | JY09 | Protein / enzyme biologic | 1.2 mg | Subcutaneous |
| Subject | JY09 | Protein / enzyme biologic | 2.4 mg | Subcutaneous |
| Background | Metformin | Small molecule | — | Oral |